According to a study conducted on mouse models, suppressing the production of boss peptides myostine protein would increase muscle mass and lead to significant improvements in heart and kidney function.
Muscular atrophy is a reduction in the mass of striated muscles which causes a partial or complete loss of function. The main consequence of atrophy is muscle weakness (asthenia), since the force that can be generated by a muscle depends (though not exclusively) on its mass.
The causes of this process can be physiological or pathological. Muscle atrophy reduces the quality of life by preventing the subject who suffers from carrying out normal daily activities (such as walking) or aggravating the risks of accidents while performing them.
What is myostine?
Myostine is a protein discovered in 1997 by scientists McPherron and Se-Jin Lee in studies on cellular differentiation and proliferation.
It is mainly produced by skeletal muscle cells (some studies have found its presence also in adipose, cardiac and bone tissue).
It is an inhibitor of muscle development and the lower its level, the greater the muscular development.
In an experiment on mice homozygous for the absence of the protein, these presented a superior muscular development compared to heterozygous mice (carriers of only one mutated gene) and normal ones. The body size was 30% higher, the muscle was hypertrophic and the weight was 2 or 3 times greater than in natural guinea pigs. Later histological analysis showed an increase in both the size of single muscle cells (hypertrophy) and their number (hyperplasia). At the same time there was a slight decrease in adipose tissue while fertility and life span remained almost unchanged.
This discovery has opened new horizons in the treatment of muscular and cardiac diseases, in sports and in cattle breeding. For example, let’s think about possible muscle regeneration following an injury, or myocardial regeneration following a heart attack.
Recently the application of bosspeptides myostine inhibitors in the treatment of muscular dystrophy has aroused particular interest.
Generalized muscular atrophy is a possible complication or comorbidity of various diseases, such as malignant tumors, AIDS, congestive heart failure, COPD, advanced chronic renal failure and severe burns; in all these cases, it may fall within a framework of cachexia (a condition of severe deterioration with hyper catabolism), generally associated with a poor prognosis.
Current research is focusing on the study and development of these potentials but there are still many hypotheses and few certainties. Studies on the role of myostine in the human body are few, often discordant, and still awaiting confirmation.